Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Horm Res Paediatr 2013;80:64-68

Occurrence of Slipped Capital Femoral Epiphysis in Children Undergoing Gonadotropin-Releasing Hormone Agonist Therapy for the Treatment of Central Precocious Puberty

Inman M.a · Hursh B.E.b · Mokashi A.a, c · Pinto T.a, c · Metzger D.L.b · Cummings E.A.a, c

Author affiliations

aDepartment of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, N.S., bDivision of Pediatric Endocrinology, BC Children's Hospital, University of British Columbia, Vancouver, B.C., and cDivision of Pediatric Endocrinology, IWK Health Centre, Dalhousie University, Halifax, N.S.,Canada

Corresponding Author

Elizabeth A. Cummings

Division of Pediatric Endocrinology, IWK Health Centre

PO Box 9700, 5850/5980 University Avenue

Halifax, NS B3K 6R8 (Canada)

E-Mail Elizabeth.cummings@dal.ca

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Obesity, age and hormone imbalances including hypothyroidism and growth hormone deficiency and therapy, but not gonadotropin-releasing hormone agonist (GnRHa) therapy, have been identified as risk factors for slipped capital femoral epiphysis (SCFE). Five of 7 reported cases describe SCFE in children shortly after GnRHa therapy cessation. Methods: We report 3 cases of SCFE that occurred in children on GnRHa therapy for the treatment of central precocious puberty (CPP) and discuss possible promoting factors. Results: An otherwise healthy 8.75-year-old girl [body mass index (BMI) Z score +1.75] developed SCFE 6.75 years into GnRHa therapy for idiopathic CPP. A second girl (with a history of acute lymphoblastic leukemia requiring total body irradiation) was 10.6 years old (BMI Z score +1.06) when she developed SCFE 3.3 years into GnRHa therapy. The third case was an 8.75-year-old female with CPP secondary to a hypothalamic hamartoma (BMI Z score +1.65) who developed bilateral SCFE 5.6 years into therapy. Conclusion: Increasing evidence suggests an association between GnRHa therapy for CPP and the occurrence of SCFE. We suggest that a lack of adequate sex hormone exposure at a ‘critical period' of bone formation may result in a weakened epiphysis that becomes susceptible to slipping.

© 2013 S. Karger AG, Basel


  1. Mul D, Hughes IA: The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159:S3-S8.
  2. Kempers MJE, Noordham C, Rouwe CW, Otten BJ: Can GnRH-agonist treatment cause slipped capital femoral epiphysis? J Pediatr Endocrinol Metab 2001;14:729-734.
  3. Yamato F, Takaya J, Higashino H, Yamanouchi Y, Suehara H, Kobayashi Y: Slipped capital femoral epiphysis during treatment of precocious puberty with a gonadotropin-releasing hormone-agonist: aetiological considerations. Eur J Pediatr 2005;164:173-174.
  4. van Puijenbroek E, Verhoef E, de Graaf L: Slipped capital femoral epiphysis associated with the withdrawal of a gonadotrophin releasing hormone. BMJ 2004;328:1353.
  5. Lehmann CL, Arons RR, Loder RT, Vitale MG: The epidemiology of slipped capital femoral epiphysis: an update. J Pediatr Orthop 2006;26:286-290.
  6. Song K, Oh C, Lee H, Kim S; Multicenter Study Committee of the Korean Pediatric Orthopedic Society: Epidemiology and demographics of slipped capital femoral epiphysis in Korea: a multicenter study by the Korean pediatric orthopedic society. J Pediatr Orthop 2009;29:683-686.
  7. Gholve PA, Cameron DB, Millis MB: Slipped capital femoral epiphysis update. Curr Opin Pediatr 2009;21:39-45.
  8. Loder RT, Wittenberg B, DeSilva G: Slipped capital femoral epiphysis associated with endocrine disorders. J Pediatr Orthop 1995;15:349-356.
    External Resources
  9. Papavasiliou KA, Kirkos JM, Kapetanos GA, Pournaras J: Potential influence of hormones in the development of slipped capital femoral epiphysis: a preliminary study. J Pediatr Orthop B 2007;16:1-5.
  10. Miyazaki O, Nishimura G, Okamoto R, Masaki H, Kumagai M, Shioda Y, Nozawa K, Kitoh H: Induction of systemic bone changes by preconditioning total body irradiation for bone marrow transplantation. Pediatr Radiol 2009;39:23-29.
  11. Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL: Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998;83:370-373.
  12. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tato L: Bone development during GH and GnRH analog treatment. Eur J Endocrinol 2004;151:S47-S54.
  13. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR: Consensus statement on the use of GnRH analogs in children. Pediatrics 2009;123:752-762.
  14. Teng L, Bui H, Bachrach L, Lee P, Gagné N, Deal C, Wilson DM: Catch-up growth in severe juvenile hypothyroidism: treatment with a GnRH analog. J Pediatr Endocrinol Metab 2004;17:345-354.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: January 10, 2013
Accepted: March 28, 2013
Published online: July 13, 2013

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 1

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: https://www.karger.com/HRP